Clinical Trials
51 trialsIpilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma
European Institute of Oncology
Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy
Sun Yat-sen University
IMAGINE
University Hospital, Essen
GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma
Suzhou Kintor Pharmaceutical Inc,
BreastImmune03
Centre Leon Berard
Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer
Northwestern University
NIVOFGFR2
Kidney Cancer Research Bureau
ANZUP2001
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
OpACIN-neo
The Netherlands Cancer Institute
Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma
National Cancer Centre, Singapore
ROME
Fondazione per la Medicina Personalizzata
Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma
Hoosier Cancer Research Network
Lowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's Lymphoma
Hospital Universitario Dr. Jose E. Gonzalez
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma
National Research Center for Hematology, Russia
AARON
Ludwig-Maximilians - University of Munich
RACE IT
Technical University of Munich
Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases
Shanghai Changzheng Hospital
REFINE
University College, London
Nivolumab+Ipilimumab+RT in MSS mCRC
Massachusetts General Hospital
A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours
Fundación de investigación HM
Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma
China Medical University, China
MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma
Momotaro-Gene Inc.
Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion
Tel-Aviv Sourasky Medical Center
Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10%
National Cancer Center, Korea
NURE-Combo
IRCCS San Raffaele
Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy
Hellenic GenitoUrinary Cancer Group
TONIC
The Netherlands Cancer Institute
UNISoN
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Nivolumab for Recurrent/Metastatic Carcinosarcoma
Yonsei University
Nivolumab, S-1 Combined With Oxaliplatin Versus Nivolumab as Neoadjuvant Therapy in Advanced Gastric Cancer
Chinese PLA General Hospital
TITAN-TCC
AIO-Studien-gGmbH
NIVALLO
Melbourne Health
ImmunoProst
Hospital Moinhos de Vento
A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers
Korean Cancer Study Group
Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.
Kidney Cancer Research Bureau
Neoadjuvant Nivolumab for Operable Esophageal Carcinoma
Samsung Medical Center
Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
Northwestern University
OASIS
Shanghai Zhongshan Hospital
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer
National Taiwan University Hospital
CheCUP
University Hospital Heidelberg
SQUINT
Fondazione Ricerca Traslazionale
NIBIT-ML1
Italian Network for Tumor Biotherapy Foundation
Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer
The First Affiliated Hospital with Nanjing Medical University
A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC
Peking University Cancer Hospital & Institute
NICE-COMBO
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma
Yonsei University
NivoM
Sheba Medical Center
ModuLung
University Hospital Regensburg